149 related articles for article (PubMed ID: 31012122)
1. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma.
Zahn J; Chan MP; Wang G; Patel RM; Andea AA; Bresler SC; Harms PW
J Cutan Pathol; 2019 Sep; 46(9):659-664. PubMed ID: 31012122
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of p16 and RB protein in eccrine porocarcinoma.
Gu LH; Ichiki Y; Kitajima Y
J Cutan Pathol; 2002 Sep; 29(8):473-9. PubMed ID: 12207741
[TBL] [Abstract][Full Text] [Related]
3. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Bosic M; Kirchner M; Brasanac D; Leichsenring J; Lier A; Volckmar AL; Oliveira C; Buchhalter I; Stögbauer F; Zivkovic-Perisic S; Goeppert B; Schirmacher P; Penzel R; Endris V; Stenzinger A
Pathology; 2018 Apr; 50(3):327-332. PubMed ID: 29269125
[TBL] [Abstract][Full Text] [Related]
4. Poroma: a review of eccrine, apocrine, and malignant forms.
Sawaya JL; Khachemoune A
Int J Dermatol; 2014 Sep; 53(9):1053-61. PubMed ID: 24697501
[TBL] [Abstract][Full Text] [Related]
5. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma.
Kervarrec T; Frouin E; Collin C; Tallet A; Tallegas M; Pissaloux D; Tirode F; Guyétant S; Samimi M; Gaboriaud P; Touzé A; Schrama D; Houben R; Tabareau-Delalande F; Neuhart A; de la Fouchardière A; Osio A; Cavelier-Balloy B; Laurent-Roussel S; Sohier P; Cyprien T; Balme B; Belzung F; Jullie ML; Cribier B; Battistella M; Macagno N
Histopathology; 2023 May; 82(6):885-898. PubMed ID: 36720791
[TBL] [Abstract][Full Text] [Related]
6. p53 protein and proliferating cell nuclear antigen in eccrine poroma and porocarcinoma. an immunohistochemical study.
Tateyama H; Eimoto T; Tada T; Inagaki H; Nakamura T; Yamauchi R
Am J Dermatopathol; 1995 Oct; 17(5):457-64. PubMed ID: 8599450
[TBL] [Abstract][Full Text] [Related]
7. Concomitant poroma and porocarcinoma.
Abarzúa Á; Álvarez-Véliz S; Moll-Manzur C
An Bras Dermatol; 2017; 92(4):550-552. PubMed ID: 28954110
[TBL] [Abstract][Full Text] [Related]
8. Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Bai M; Vlachonikolis J; Agnantis NJ; Tsanou E; Dimou S; Nicolaides C; Stefanaki S; Pavlidis N; Kanavaros P
Mod Pathol; 2001 Nov; 14(11):1105-13. PubMed ID: 11706071
[TBL] [Abstract][Full Text] [Related]
9. P53 protein expression in eccrine poroma and porocarcinoma.
Akalin T; Sen S; Yücetürk A; Kandiloğlu G
Am J Dermatopathol; 2001 Oct; 23(5):402-6. PubMed ID: 11801771
[TBL] [Abstract][Full Text] [Related]
10. Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma.
Russell-Goldman E; Hornick JL; Hanna J
J Cutan Pathol; 2021 Mar; 48(3):403-410. PubMed ID: 33222286
[TBL] [Abstract][Full Text] [Related]
11. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
12. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
[TBL] [Abstract][Full Text] [Related]
13. Significance of cyclin D1-, product of retinoblastoma (pRb), p53, p63 and p73 expression in eccrine poroma and eccrine porocarcinoma.
Chen SY; Takeuchi S; Moroi Y; Kido M; Hayashida S; Qian Y; Tomoeda H; Uenotsuchi T; Urabe K; Furue M; Tu YT
J Dermatol Sci; 2009 Oct; 56(1):69-72. PubMed ID: 19643581
[No Abstract] [Full Text] [Related]
14. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
Subhawong AP; Subhawong T; Nassar H; Kouprina N; Begum S; Vang R; Westra WH; Argani P
Am J Surg Pathol; 2009 Feb; 33(2):163-75. PubMed ID: 18936692
[TBL] [Abstract][Full Text] [Related]
15. Spindle cell porocarcinoma with a novel YAP1::MAML3 fusion.
Li P; Busam KJ
J Cutan Pathol; 2024 Mar; 51(3):226-229. PubMed ID: 38088454
[TBL] [Abstract][Full Text] [Related]
16. A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: Review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility.
Parra O; Kerr DA; Bridge JA; Loehrer AP; Linos K
J Cutan Pathol; 2021 Jan; 48(1):95-101. PubMed ID: 32757412
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance Imaging Characteristics of Poroma and Porocarcinoma.
Kawaguchi M; Kato H; Imada H; Miyazaki T; Matsuyama K; Seishima M; Matsuo M
J Comput Assist Tomogr; 2021 May-Jun 01; 45(3):447-451. PubMed ID: 33797441
[TBL] [Abstract][Full Text] [Related]
18. [Tumors with poroid features: a clinicopathologic analysis of 45 cases].
Yao H; Liu J; Su J; Zheng Jie ; Liao S
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):179-83. PubMed ID: 26268752
[TBL] [Abstract][Full Text] [Related]
19. An Unusual Case of a Scrotal Porocarcinoma and Review of the Literature.
Hartsough EM; Moran J; Devins K; Wszolek M; Cornejo KM
Am J Dermatopathol; 2023 Jan; 45(1):51-55. PubMed ID: 36484607
[TBL] [Abstract][Full Text] [Related]
20. Eccrine poroma and porocarcinoma on the same unusual location: report on two cases.
Ma H; Liao M; Qiu S; Lu R; Lu C
An Bras Dermatol; 2015; 90(3 Suppl 1):69-72. PubMed ID: 26312678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
